DACS
BLTE

Dymon Asia Capital (Singapore)’s Belite Bio BLTE Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Hold
1,900
– – 0.01% 219
2026
Q1 		$303K Buy
+1,900
New +$320K 0.03% 217

Other funds holding BLTE

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HNWAG
High Net Worth Advisory Group Naples, Florida $471M AUM 22.07% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EFMH
E Fund Management (HK) Central, Hong Kong $302M AUM 64.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
WPA
West Paces Advisors Atlanta, Georgia $596M AUM 22.29% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s BLTE Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) held its Belite Bio (BLTE) position steady in Q2 2026 at 1,900 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #219.

Dymon Asia Capital (Singapore) first reported a position in BLTE in Q1 2026 and has held it in 2 quarters since. The position peaked at $303K in Q1 2026. 12 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 1,900 shares of Belite Bio worth $293K as of Q2 2026.
  • Dymon Asia Capital (Singapore) left its Belite Bio share count unchanged in Q2 2026.
  • Belite Bio made up 0.01% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #219 holding.
  • Dymon Asia Capital (Singapore) first reported a position in Belite Bio in Q1 2026 and has held it in 2 quarters since.
  • Dymon Asia Capital (Singapore)'s Belite Bio position peaked at $303K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.